Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04337203
Other study ID # IRB00064683
Secondary ID WFBCCC 994201P50
Status Completed
Phase N/A
First received
Last updated
Start date September 8, 2020
Est. completion date May 31, 2022

Study information

Verified date June 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is conduct a pilot study testing the study protocols, implementation program, and mixed-methods data collection.


Description:

Primary Objectives: • To evaluate how successfully SHARE-S can be implemented into clinical care as characterized by rates of enrollment. Investigators hypothesize >30% of patients e-referred to SHARE-S will enroll. Secondary Objectives: - To assess additional implementation outcomes that evaluate preliminary implementation success (i.e., further assessment of adoption, acceptability, appropriateness, further assessment of feasibility, and fidelity). - To describe service outcome variability to inform future studies. Investigators will assess service outcomes relevant to Commission on Cancer requirements by reporting annual estimates for: (1) the estimated number of patients impacted by SHARE-S; (2) the cancer sites impacted by SHARE-S; and the (3) resources/processes utilized to enhance each of the chosen services if barriers were encountered. We will also assess safety and perceived patient-centeredness of care. - To describe patient health outcome variability to inform future studies (i.e., social role, physical functioning, anxiety, depression, fatigue, sleep disturbance, pain, cancer-specific quality of life, health behaviors, patient autonomy, self-efficacy for managing cancer, engagement with the survivorship care plan document, and satisfaction with care). - To evaluate the Implementation Program we will assess key milestones and processes for this pilot study of the Implementation Stage measured at the clinic level. - To qualitatively assess implementation barriers and facilitators using semi-structured interviews that will be audio-recorded. - To examine how study results vary by cancer type.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date May 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Adults =18 years of age - Documented or planned cancer survivorship visit - Have a texting enabled telephone - Cognitively able to complete study procedures as judged by the study team - Able to understand, read and write English Children under the age of 18 with cancer will be excluded due to the potentially different self-management support intervention needs of this population that will likely include parental involvement. Results from this research may inform future studies in children with cancer under 18 who should be researched separately. Exclusion Criteria - Declined participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
SHARE-S Implementation Program
The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).

Locations

Country Name City State
United States Wake Forest Baptist Comprehensive Cancer Center Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Enrolled Out of Those Electronically Referred Using a 95% confidence interval (CI) to determine the range of estimates that are consistent with our data. Investigators will track the number of new patients seen in the Survivorship Clinic, and the percent who agree to be referred to SHARE-S. 1 year, 8 months
Secondary Adoption - Number of Electronically Referred Patients - Those Possible [Based on Chart Review] Using a 95% confidence interval to determine the range of estimates that are consistent with our data. Investigators will track the number of new patients seen in the Survivorship Clinic, and the percent who agree to enroll in SHARE-S 1 year, 8 months
Secondary Acceptability of Intervention Measure This measure will be used along with qualitative feedback among participants using a mixed-methods to assess acceptability of intervention with different cancer types. Acceptability ranges from 1-5 with higher scores indicating more acceptability. Up to 30 days after the final intervention session.
Secondary Appropriateness of Intervention Measure This measure will be used along with qualitative feedback among participants using a mixed-methods to assess appropriateness of intervention with different cancer types. Appropriateness ranges from 1-5 with higher scores meaning more appropriateness. Up to 30 days after the final intervention session.
Secondary Number of Participants Enrolled Per Month This will be defined as the average number of participants that enroll per month that the study is open to enrollment. 1 year, 8 months
Secondary Feasibility of Intervention Measure This measure will be used along with qualitative feedback among participants using a mixed-methods to assess feasibility of intervention with different cancer types. Feasibility ranges from 1-5 with higher scores indicating more feasibility. Up to 30 days after the final intervention session.
Secondary Retention Rates Retention is defined as participants that complete the follow up assessment. Up to 30 days after the final intervention session.
Secondary Number of Participants Adhering to Text Responses Defined as participants that adhere to responding to text messages received during intervention. 1 year, 8 months
Secondary Participant Adherence to Coaching Sessions Defined as adherence to completing coaching sessions during the intervention. 1 year, 8 months
Secondary Length of Coaching Sessions Defined as how long each completed coaching sessions lasted during the intervention. Up to 30 days after the final intervention session.
Secondary Number of Coaching Sessions Completed Defined as an observational checklist completed for a subset of coaching sessions. 1 year, 8 months
Secondary Total Number of Patients Enrolled Number of patients enrolled will be defined as overall participants for the entirety of the study. 1 year, 8 months
Secondary Frequency of Adverse Events Adverse events related to the intervention will be assessed in adverse event log. Up to 30 days after the final intervention session.
Secondary HEAL Patient-Provider Connection Patient reported measure of patient-centered communication/relatedness completed only at follow-up. Range 0-35 with higher scores indicating better communication. Up to 30 days after the final intervention session.
Secondary Patient-Reported Health Outcomes PROMIS Profile 29 Questionnaire to assess the social role (0-100), physical functioning (0-100), anxiety (0-100), depression (0-100), fatigue (0-100), sleep disturbance (0-100), pain interference (0-100), pain intensity (0-10). Lower scores indicate less of construct. At baseline and up to 30 days after the final intervention session.
Secondary 36-Item Short Form Survey (SF-36) Participants will only answer the single item question that provides an indication of perceived change in health. Score range: 1 - excellent health, 2 - very good health, 3 - good health, 4 - fair health and 5 - poor health. At baseline and up to 30 days after the final intervention session.
Secondary Cancer-specific Quality of Life in Adult Cancer Survivors (QLACS) Questionnaire Investigators will only assess the quality of life of adult cancer survivors measuring domains of cancer survivorship that are cancer-specific. Cancer-Specific Quality of Life (range 15-105) - higher score indicates more quality of life; Benefits of Having Cancer (range 4-28) - higher score indicates more benefits; Positive Feelings (range 4-28) - lower score indicates more positive feelings. At baseline and up to 30 days after the final intervention session.
Secondary Index of Autonomous Functioning - Self Congruence Subscale Only The Index of Autonomous Functioning - self congruence subscale only. 5 Items were paired with a Likert-type scale with 1 = "not at all true", 2 = "a bit true", 3 = "somewhat true", 4 = "mostly true", and 5 = "completely true." Mean score is average of 5 items. Higher mean score indicate a higher level of self congruence functioning. At baseline and up to 30 days after the final intervention session.
Secondary Self-Efficacy to Manage Chronic Disease Questionnaire A questionnaire made up of 6-items on a visual analog scale, ranging from 1 (not at all confident) to 10 (totally confident). Higher the mean score indicates higher self-efficacy. At baseline and up to 30 days after the final intervention session.
Secondary Engagement With the Survivorship Care Plan Self-reported use of the care plan since enrolled on the study. 1 year, 8 months
Secondary Satisfaction of Care Participants will evaluate their overall satisfaction with their care after the study intervention. Mean of Likert scale. 1=very poor, 5=very good. Up to 30 days after the final intervention session.
Secondary Health Behaviors Questionnaire - Tobacco Use Participants will be asked about their tobacco use within the last seven days. Tobacco use is scored 1=yes, 0=no. Higher values represent more participants were tobacco users. At baseline and up to 30 days after the final intervention session.
Secondary Health Behaviors Questionnaire - Alcohol Use Disorder Participants will be asked individual questions about their alcohol use. Alcohol use disorder is on a scale of 0-12 with higher scores indicating more hazardous; men = 4, women = 3 is considered hazardous. At baseline and up to 30 days after the final intervention session.
Secondary Health Behaviors Questionnaire - Physical Activity Participants will be asked individual questions about their physical activity. Physical activity is minutes/week with <90 minutes considered insufficient. At baseline and up to 30 days after the final intervention session.
Secondary Health Behaviors Questionnaire - Fruit and Vegetable Intake Participants will be asked individual questions about their fruit and vegetable intake. Mean for the responses were calculated in cups so ½ to 1 cup = 0.75 cups, at least 2-3 cups for both considered sufficient. At baseline and up to 30 days after the final intervention session.
Secondary Health Behaviors Questionnaire - Mindfulness Practice Participants will be asked individual questions how many days/week they practice mindfulness. At baseline and up to 30 days after the final intervention session.
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery